These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8610104)

  • 21. Utilizing Immunocytokines for Cancer Therapy.
    Runbeck E; Crescioli S; Karagiannis SN; Papa S
    Antibodies (Basel); 2021 Mar; 10(1):. PubMed ID: 33803078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of interleukin-2 in immunostimulation and immunosuppression.
    Pol JG; Caudana P; Paillet J; Piaggio E; Kroemer G
    J Exp Med; 2020 Jan; 217(1):. PubMed ID: 31611250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.
    Schmid AS; Tintor D; Neri D
    J Biotechnol; 2018 Apr; 271():29-36. PubMed ID: 29438784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer.
    Padayachee ER; Biteghe FAN; Malindi Z; Bauerschlag D; Barth S
    Transfus Med Hemother; 2017 Sep; 44(5):303-310. PubMed ID: 29070975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delivering safer immunotherapies for cancer.
    Milling L; Zhang Y; Irvine DJ
    Adv Drug Deliv Rev; 2017 May; 114():79-101. PubMed ID: 28545888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different tissue distribution properties for glycosylation variants of fusion proteins containing the p40 subunit of murine interleukin-12.
    Bootz F; Venetz D; Ziffels B; Neri D
    Protein Eng Des Sel; 2016 Oct; 29(10):445-455. PubMed ID: 27515704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.
    Morris ZS; Guy EI; Francis DM; Gressett MM; Werner LR; Carmichael LL; Yang RK; Armstrong EA; Huang S; Navid F; Gillies SD; Korman A; Hank JA; Rakhmilevich AL; Harari PM; Sondel PM
    Cancer Res; 2016 Jul; 76(13):3929-41. PubMed ID: 27197149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences.
    Chaurasiya S; Hew P; Crosley P; Sharon D; Potts K; Agopsowicz K; Long M; Shi C; Hitt MM
    Cancer Gene Ther; 2016 Jun; 23(6):178-87. PubMed ID: 27151235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.
    Young PA; Morrison SL; Timmerman JM
    Semin Oncol; 2014 Oct; 41(5):623-36. PubMed ID: 25440607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches.
    Daniotti JL; Vilcaes AA; Torres Demichelis V; Ruggiero FM; Rodriguez-Walker M
    Front Oncol; 2013 Dec; 3():306. PubMed ID: 24392350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunocytokines: a review of molecules in clinical development for cancer therapy.
    List T; Neri D
    Clin Pharmacol; 2013; 5(Suppl 1):29-45. PubMed ID: 23990735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spontaneous nonthymic tumors in SCID mice.
    Huang P; Westmoreland SV; Jain RK; Fukumura D
    Comp Med; 2011 Jun; 61(3):227-34. PubMed ID: 21819692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.
    Gubbels JA; Gadbaw B; Buhtoiarov IN; Horibata S; Kapur AK; Patel D; Hank JA; Gillies SD; Sondel PM; Patankar MS; Connor J
    Cancer Immunol Immunother; 2011 Dec; 60(12):1789-800. PubMed ID: 21792658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidelines for the welfare and use of animals in cancer research.
    Workman P; Aboagye EO; Balkwill F; Balmain A; Bruder G; Chaplin DJ; Double JA; Everitt J; Farningham DA; Glennie MJ; Kelland LR; Robinson V; Stratford IJ; Tozer GM; Watson S; Wedge SR; Eccles SA;
    Br J Cancer; 2010 May; 102(11):1555-77. PubMed ID: 20502460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-GD2 antibody therapy for GD2-expressing tumors.
    Navid F; Santana VM; Barfield RC
    Curr Cancer Drug Targets; 2010 Mar; 10(2):200-9. PubMed ID: 20201786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.
    Ribas A; Kirkwood JM; Atkins MB; Whiteside TL; Gooding W; Kovar A; Gillies SD; Kashala O; Morse MA
    J Transl Med; 2009 Jul; 7():68. PubMed ID: 19640287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
    King DM; Albertini MR; Schalch H; Hank JA; Gan J; Surfus J; Mahvi D; Schiller JH; Warner T; Kim K; Eickhoff J; Kendra K; Reisfeld R; Gillies SD; Sondel P
    J Clin Oncol; 2004 Nov; 22(22):4463-73. PubMed ID: 15483010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibody-based therapy for neuroblastoma.
    Cheung NK
    Curr Oncol Rep; 2000 Nov; 2(6):547-53. PubMed ID: 11122891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction.
    Lode HN; Xiang R; Pertl U; Förster E; Schoenberger SP; Gillies SD; Reisfeld RA
    J Clin Invest; 2000 Jun; 105(11):1623-30. PubMed ID: 10841521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.
    Lode HN; Xiang R; Duncan SR; Theofilopoulos AN; Gillies SD; Reisfeld RA
    Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8591-6. PubMed ID: 10411920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.